Development of a novel, RNA-interference-based therapeutic to treat prostate cancer

Project: Research project

Project Details

StatusActive
Effective start/end date9/19/248/31/25

Funding

  • NUAgo Therapeutics, Inc. (FP00004348 // 1R41CA287846-01A1)
  • National Cancer Institute (FP00004348 // 1R41CA287846-01A1)